{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=blood+samples+%282%29",
    "query": {
      "intervention": "blood samples (2)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10440,
    "total_pages": 1044,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=blood+samples+%282%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-14T18:22:55.750Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00026221",
      "title": "Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Melanoma",
        "Stage IV Skin Melanoma"
      ],
      "interventions": [
        {
          "name": "Recombinant Interferon Alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2001-11",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2016-03-17",
      "last_synced_at": "2026-09-14T18:22:55.750Z",
      "location_count": 2,
      "location_summary": "Cincinnati, Ohio • Columbus, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00026221"
    },
    {
      "nct_id": "NCT01203514",
      "title": "The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Infant, Newborn",
        "Infant, Low Birth Weight",
        "Infant, Small for Gestational Age",
        "Infant, Premature",
        "Anemia, Neonatal"
      ],
      "interventions": [
        {
          "name": "Erythropoietin",
          "type": "DRUG"
        },
        {
          "name": "Sham Comparator",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NICHD Neonatal Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "24 Hours",
        "maximum_age": "96 Days",
        "sex": "ALL",
        "summary": "24 Hours to 96 Days"
      },
      "enrollment_count": 318,
      "start_date": "1997-08",
      "completion_date": "2000-08",
      "has_results": false,
      "last_update_posted_date": "2017-09-26",
      "last_synced_at": "2026-09-14T18:22:55.750Z",
      "location_count": 9,
      "location_summary": "New Haven, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01203514"
    },
    {
      "nct_id": "NCT03260504",
      "title": "Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Clear Cell Renal Cell Carcinoma",
        "Stage III Renal Cell Cancer",
        "Stage IV Renal Cell Cancer",
        "Metastatic Clear Cell Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2018-08-28",
      "completion_date": "2022-07-26",
      "has_results": true,
      "last_update_posted_date": "2025-12-08",
      "last_synced_at": "2026-09-14T18:22:55.750Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03260504"
    },
    {
      "nct_id": "NCT06996652",
      "title": "An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "REM Sleep Behavior Disorder"
      ],
      "interventions": [
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 108,
      "start_date": "2026-08-17",
      "completion_date": "2030-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-09-14T18:22:55.750Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • Aurora, Colorado • North Haven, Connecticut + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "North Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06996652"
    },
    {
      "nct_id": "NCT01815749",
      "title": "Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Grade III Lymphomatoid Granulomatosis",
        "Cutaneous B-cell Non-Hodgkin Lymphoma",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Intraocular Lymphoma",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Post-transplant Lymphoproliferative Disorder",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Grade III Lymphomatoid Granulomatosis",
        "Recurrent Adult Immunoblastic Large Cell Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Hairy Cell Leukemia",
        "Small Intestine Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "Testicular Lymphoma",
        "Waldenström Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "autologous hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2013-10-08",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-09-14T18:22:55.750Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01815749"
    },
    {
      "nct_id": "NCT04016558",
      "title": "Behavioral Approaches to Reducing Diabetes Distress and Improving Glycemic Control",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 1 Diabetes",
        "Diabetes Distress"
      ],
      "interventions": [
        {
          "name": "StreamLine",
          "type": "BEHAVIORAL"
        },
        {
          "name": "TunedIn",
          "type": "BEHAVIORAL"
        },
        {
          "name": "FixIt",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 296,
      "start_date": "2019-09-15",
      "completion_date": "2023-02-15",
      "has_results": true,
      "last_update_posted_date": "2025-10-28",
      "last_synced_at": "2026-09-14T18:22:55.750Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04016558"
    },
    {
      "nct_id": "NCT02887755",
      "title": "Assessing the Feasibility of a Novel Non-Invasive Sensor for Guiding Wounded Warrior Rehabilitation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Rehabilitation Post-amputation"
      ],
      "interventions": [
        {
          "name": "Near-Infrared Spectroscopy (NIRS) Sensor",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Henry M. Jackson Foundation for the Advancement of Military Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 20,
      "start_date": "2015-12",
      "completion_date": "2017-10",
      "has_results": false,
      "last_update_posted_date": "2018-04-02",
      "last_synced_at": "2026-09-14T18:22:55.750Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02887755"
    },
    {
      "nct_id": "NCT05313243",
      "title": "Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "T-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Brentuximab vedotin",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2023-07-10",
      "completion_date": "2028-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-09-14T18:22:55.750Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut • Boston, Massachusetts",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05313243"
    },
    {
      "nct_id": "NCT01231633",
      "title": "Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Macular Edema",
        "Central Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Ozurdex",
          "type": "DRUG"
        },
        {
          "name": "Avastin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Long Island Vitreoretinal Consultants",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2010-09",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2018-04-03",
      "last_synced_at": "2026-09-14T18:22:55.750Z",
      "location_count": 4,
      "location_summary": "Toms River, New Jersey • Great Neck, New York • Hauppauge, New York + 1 more",
      "locations": [
        {
          "city": "Toms River",
          "state": "New Jersey"
        },
        {
          "city": "Great Neck",
          "state": "New York"
        },
        {
          "city": "Hauppauge",
          "state": "New York"
        },
        {
          "city": "Riverhead",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01231633"
    },
    {
      "nct_id": "NCT01971515",
      "title": "First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "MSC2363318A",
          "type": "DRUG"
        },
        {
          "name": "MSC2363318A plus Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "MSC2363318A plus Tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2013-12-13",
      "completion_date": "2018-08-09",
      "has_results": false,
      "last_update_posted_date": "2018-09-19",
      "last_synced_at": "2026-09-14T18:22:55.750Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01971515"
    }
  ]
}